Treatment of hypereosinophilic syndromes-the first 100 years

J. H. Butterfield, C. R. Weiler

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Treatment of the hypereosinophilic syndrome (HES) has advanced rapidly and prevention of end organ damage previously associated with the disorders is now possible in most patients who have had a timely diagnosis. Tried and true medications such as prednisone, hydroxyurea, and interferon-alpha (IFN-aα) continue to play a valuable role in treating HES and their cost is modest. Newer medications included pegylated forms of IFN-aα and IFN-α2b, first- and second-generation tyrosine kinase inhibitors (imatinib mesylate, nilotinib), and monoclonal antibodies to interleukin (IL)-5 and CD52. The combination of better understanding of HES and better medications now provide the clinician with an improved ability to control unregulated proliferation of eosinophils.

Original languageEnglish (US)
Pages (from-to)182-191
Number of pages10
JournalSeminars in Hematology
Volume49
Issue number2
DOIs
StatePublished - Apr 2012

Fingerprint

Hypereosinophilic Syndrome
interferon alfa-2b
Hydroxyurea
Interleukin-5
Prednisone
Eosinophils
Interferon-alpha
Protein-Tyrosine Kinases
Therapeutics
Monoclonal Antibodies
Costs and Cost Analysis

ASJC Scopus subject areas

  • Hematology

Cite this

Treatment of hypereosinophilic syndromes-the first 100 years. / Butterfield, J. H.; Weiler, C. R.

In: Seminars in Hematology, Vol. 49, No. 2, 04.2012, p. 182-191.

Research output: Contribution to journalArticle

Butterfield, J. H. ; Weiler, C. R. / Treatment of hypereosinophilic syndromes-the first 100 years. In: Seminars in Hematology. 2012 ; Vol. 49, No. 2. pp. 182-191.
@article{da10fe062dad47cc96d5968fdef4ead8,
title = "Treatment of hypereosinophilic syndromes-the first 100 years",
abstract = "Treatment of the hypereosinophilic syndrome (HES) has advanced rapidly and prevention of end organ damage previously associated with the disorders is now possible in most patients who have had a timely diagnosis. Tried and true medications such as prednisone, hydroxyurea, and interferon-alpha (IFN-aα) continue to play a valuable role in treating HES and their cost is modest. Newer medications included pegylated forms of IFN-aα and IFN-α2b, first- and second-generation tyrosine kinase inhibitors (imatinib mesylate, nilotinib), and monoclonal antibodies to interleukin (IL)-5 and CD52. The combination of better understanding of HES and better medications now provide the clinician with an improved ability to control unregulated proliferation of eosinophils.",
author = "Butterfield, {J. H.} and Weiler, {C. R.}",
year = "2012",
month = "4",
doi = "10.1053/j.seminhematol.2012.01.001",
language = "English (US)",
volume = "49",
pages = "182--191",
journal = "Seminars in Hematology",
issn = "0037-1963",
publisher = "W.B. Saunders Ltd",
number = "2",

}

TY - JOUR

T1 - Treatment of hypereosinophilic syndromes-the first 100 years

AU - Butterfield, J. H.

AU - Weiler, C. R.

PY - 2012/4

Y1 - 2012/4

N2 - Treatment of the hypereosinophilic syndrome (HES) has advanced rapidly and prevention of end organ damage previously associated with the disorders is now possible in most patients who have had a timely diagnosis. Tried and true medications such as prednisone, hydroxyurea, and interferon-alpha (IFN-aα) continue to play a valuable role in treating HES and their cost is modest. Newer medications included pegylated forms of IFN-aα and IFN-α2b, first- and second-generation tyrosine kinase inhibitors (imatinib mesylate, nilotinib), and monoclonal antibodies to interleukin (IL)-5 and CD52. The combination of better understanding of HES and better medications now provide the clinician with an improved ability to control unregulated proliferation of eosinophils.

AB - Treatment of the hypereosinophilic syndrome (HES) has advanced rapidly and prevention of end organ damage previously associated with the disorders is now possible in most patients who have had a timely diagnosis. Tried and true medications such as prednisone, hydroxyurea, and interferon-alpha (IFN-aα) continue to play a valuable role in treating HES and their cost is modest. Newer medications included pegylated forms of IFN-aα and IFN-α2b, first- and second-generation tyrosine kinase inhibitors (imatinib mesylate, nilotinib), and monoclonal antibodies to interleukin (IL)-5 and CD52. The combination of better understanding of HES and better medications now provide the clinician with an improved ability to control unregulated proliferation of eosinophils.

UR - http://www.scopus.com/inward/record.url?scp=84858772703&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84858772703&partnerID=8YFLogxK

U2 - 10.1053/j.seminhematol.2012.01.001

DO - 10.1053/j.seminhematol.2012.01.001

M3 - Article

C2 - 22449628

AN - SCOPUS:84858772703

VL - 49

SP - 182

EP - 191

JO - Seminars in Hematology

JF - Seminars in Hematology

SN - 0037-1963

IS - 2

ER -